How Natera ctDNA Partnership Around STELLAR-316 At Exelixis (EXEL) Has Changed Its Investment Story [Yahoo! Finance]
Exelixis, Inc. (EXEL)
Last exelixis, inc. earnings: 2/25 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.exelixis.com/phoenix.zhtml?c=120923&p=irol-mediaresources
Company Research
Source: Yahoo! Finance
zanzalintinib with and without an immune checkpoint inhibitor in intersected stage II/III colorectal cancer, using Signatera to track circulating tumor DNA in a high-risk, MRD-positive subgroup lacking approved U.S. treatment options. This move highlights Exelixis' effort to extend zanzalintinib beyond metastatic disease into earlier-stage colorectal cancer, potentially addressing a clearly defined, genomically selected patient population with significant unmet medical need. Against this backdrop, we'll examine how using Signatera to target MRD-positive colorectal cancer patients could reshape Exelixis' investment narrative. The end of cancer? These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's. To own Exelixis, you need to believe zanzalintinib can gradually take over as a meaningful second pillar as CABOMETYX ages. The Natera collaboration for STELLAR-316 helps reinforce the colorectal can
Show less
Read more
Impact Snapshot
Event Time:
EXEL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EXEL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EXEL alerts
High impacting Exelixis, Inc. news events
Weekly update
A roundup of the hottest topics
EXEL
News
- Exelixis Announces Preliminary Fiscal Year 2025 Financial Results, Provides 2026 Financial Guidance and Outlines Key Priorities and Milestones for 2026 [Yahoo! Finance]Yahoo! Finance
- Exelixis Announces Preliminary Fiscal Year 2025 Financial Results, Provides 2026 Financial Guidance and Outlines Key Priorities and Milestones for 2026Business Wire
- Assessing Exelixis (EXEL) Valuation After Zanzalintinib Phase 3 Success And STELLAR-316 Trial Plans [Yahoo! Finance]Yahoo! Finance
- Exelixis (NASDAQ:EXEL) had its "buy" rating reaffirmed by analysts at HC Wainwright.MarketBeat
- Is It Time To Reassess Exelixis (EXEL) After Strong Multi-Year Share Price Gains [Yahoo! Finance]Yahoo! Finance
EXEL
Earnings
- 11/4/25 - Beat
EXEL
Sec Filings
- 1/12/26 - Form 8-K
- 1/5/26 - Form SCHEDULE
- 12/12/25 - Form 144
- EXEL's page on the SEC website